Jyh-Cherng Yu

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus

Kristen N. Stevens, Zachary Fredericksen, Celine M. Vachon et al. · Cancer Research · 2012 · 107 citations · Full text

Medicine, Genetics, Oncology +17

Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium†

Jonine D. Figueroa, Montserrat García‐Closas, Manjeet K. Humphreys et al. · Human Molecular Genetics · 2011 · 80 citations · Full text

Life Sciences, Genetics, Oncology +17

Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study

Olivier Brouckaert, Anja Rudolph, Annouschka Laenen et al. · Breast Cancer Research · 2017 · 60 citations · Full text

Medicine, Biostatistics, Oncology +17

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17